On 10 March 2026, Sandoz announced the creation of a new global biosimilar development, manufacturing and supply unit, which will come into effect on 1 April 2026.
According to Sandoz, separating the biosimilar and generic development and manufacturing units will allow for more tailored operations, faster decision making and improved alignment. The announcement noted that biosimilars and generics have different development, manufacturing and supply requirements, making this structural separation beneficial to address the increasingly divergent market dynamics.
Sandoz’s CEO said it was the “start of an unprecedented ‘golden decade’ for patient access, with medicines worth more than USD 650 billion dollars set to lose exclusivity over the next 10 years”. The restructure will create a strategic opportunity for Sandoz to accelerate full vertical integration of biosimilar development, manufacturing and supply and prepare for major market opportunities.